Corline Biomedical AB (FRA:IZ7) Moat Score: 0/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IZ7 Corline Biomedical AB FRA:IZ7
43 GF Score
Price €1.55
GF Value €0.45
! 3 Warning Signs
View Full Analysis

What is Corline Biomedical AB Moat Score?

Corline Biomedical AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Corline Biomedical AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Corline Biomedical AB might have No Moat - No discernible moat.

Corline Biomedical AB  (FRA:IZ7) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Corline Biomedical AB Moat Score Related Terms

FRA:IZ7
43GF Score
Corline Biomedical AB FRA:IZ7
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?

Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued. The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.

Key valuation signals for FRA:IZ7:

  • Moat Score: 0
  • GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corline Biomedical AB Business Description

Other Exchanges CLBIO:Sweden
Address Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score

Get the complete analysis for FRA:IZ7

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€0.45
GF Value